Clinical study of Jankistomig
Latest Information Update: 24 Jun 2025
At a glance
- Drugs Jankistomig (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 24 Jun 2025 New trial record
- 18 Jun 2025 According to LOTTE BIOLOGICS media release, announced on June 19, 2025 that it has signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma. This manufacturing collaboration marks a significant milestone in our commitment to advancing Jankistomig with speed and precision. Partnering with Lotte's proven biomanufacturing capabilities enhances our operational readiness and supports our rapid path to IND submission and clinical trial initiation.